UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/572,826	10/16/2006	Ziping Liu	101193-1P US	3323
ASTRA ZENECA PHARMACEUTICALS LP GLOBAL INTELLECTUAL PROPERTY			EXAMINER	
			SHAMEEM, GOLAM M	
1800 CONCORD PIKE WILMINGTON, DE 19850-5437		ART UNIT	PAPER NUMBER	
			1626	
			MAIL DATE	DELIVERY MODE
			06/02/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/572,826	LIU ET AL.			
Office Action Summary	Examiner	Art Unit			
	Golam M. M. Shameem	1626			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 14 Ma     This action is <b>FINAL</b> . 2b)☑ This     Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4)  Claim(s) 1-5 and 8-16 is/are pending in the approach 4a) Of the above claim(s) 5, 8, 9 and 11-16 is/a  5)  Claim(s) is/are allowed.  6)  Claim(s) 1-4 and 10 is/are rejected.  7)  Claim(s) is/are objected to.  8)  Claim(s) are subject to restriction and/or are subject to restriction and/or are subject to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the content of	re withdrawn from consideration. relection requirement. r. epted or b) □ objected to by the B	≣xaminer.			
Replacement drawing sheet(s) including the correcti  11) The oath or declaration is objected to by the Ex-		• • • • • • • • • • • • • • • • • • • •			
Priority under 35 U.S.C. § 119		, tollon on lond 1 to 1 to 2			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 06/20/2006.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate			

## **DETAILED ACTION**

### **Priority**

This application is a 371 of PCT/GB04/04112 09/24/2004, is acknowledged.

#### Status of Claims

Claims 1-5 and 8-16 are currently pending in the application. Claims 6 and 7 were canceled.

Receipt is acknowledged of amendment / response filed on May 14, 2009 and that has been entered.

Claims 5, 8, 9, and 11-16 are withdrawn from further consideration pursuant to 37 C.F.R. 1.142 (b) as being drawn to a non-elected subject matter.

## Information Disclosure Statement

Receipt is acknowledged of Information Disclosure Statement (IDS), filed on 06/20/2006, which has been entered in the file.

#### Response to Election/Restriction

In response to the restriction requirements, Applicants have elected Group I, which includes claims 1-4, and 10 drawn to a compound of formula I, and the elected species as set forth and disclosed in Example 20, without traverse (Response, page 1), is acknowledged. Because Applicants did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a). Therefore, the requirement for restriction is still deemed proper.

Applicants preserve their right to file a divisional on the non-elected subject matter.

Art Unit: 1626

Page 3

As set forth in the restriction requirement and an election of a single compound (or set of

compounds), the invention will encompass all compounds that fall within the scope of the search

is as follows:

A compound of the formula I wherein:

R<sup>1</sup> is limited to C<sub>3-6</sub>heterocyclyl-C<sub>1-6</sub>alkyl,

R<sup>2</sup> is as claimed except halogen or cyano substitution,

Ar is  $C_{6-10}$ aryl only,

R<sup>3</sup> is as claimed,

R<sup>4</sup> is as claimed and all other variables are as defined.

As a result of the election and the corresponding scope of the compound identified, claims 5, 8, 9, and 11-16 and the remaining subject matter of claims 1-4, and 10 are withdrawn from further consideration pursuant to 37 CFR 1.142 (b) as being drawn to non-elected inventions. The withdrawn subject matter of claims 5, 8, 9, and 11-16 is properly restricted as it differs materially in structure and in element from the elected subject matter supra so as to be patentably distinct there from.

**Double Patenting** 

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Art Unit: 1626

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-4, and 10, are rejected under the judicially created doctrine of obviousness-type double patenting, as being unpatentable over claims 1-4, and 10 of co-pending Application No. 10/572,825 (US '825), over claims 1-4, and 18 of co-pending Application No. 10/572,929 (US '929), over claims 1-4, and 11 of co-pending Application No. 11/575,695 (US '695), over claims 1-4, and 11 of co-pending Application No. 11/575,688 (US '688), over claims 1-4, and 11 of copending Application No. 11/575,670 (US '670), over claims 1-4, and 12 of co-pending Application No. 11/575,685 (US '685), and also over claims 1-5 and 12 of co-pending Application No. 11/575,691 (US '691). Although the conflicting claims are not identical, they are not patentably distinct from each other because all sets of claims are drawn to the same art recognized subject matter. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The compounds taught by copending applications are similar to instant application because a reference anticipating one set of claim will render the other obvious and it would have been obvious to one of ordinary skill in the art at the time of the invention was made since co-pending applications teach the generic compounds, compositions and their methods of use which are similar to the instantly claimed invention.

The subject matter claimed in the instant application is fully disclosed and covered in the co-pending Applications US '825, US '929, US '695, US '688, US '670, US '685 or US '691. Therefore, the disclosures of US '825, US '929, US '695, US '688, US '670, US '685 or US '691 that teach many permutation and combination substitutions, which would easily place Applicants invention in possession of the public at the time of Applicants invention was filed.

Art Unit: 1626

The indiscriminate selection of "some" among "many" is *prima facie* obvious, *In re Lemin*, 141 USPQ 814 (1964). Therefore, in the instant case, one skilled in the chemical art would be motivated to choose to replace variable substitutions in permutation and combinations in core formula I to obtain the desired products in view of the known teaching of the art. The claimed compounds are so closely related structurally to the homologous and /or analogous compounds of the reference as to be structurally obvious therefore in the absence of any unobviousness or unexpected properties. Moreover, any other differences are but obvious structural modifications, which would be apparent to one skilled in the chemical art that can use similar substitutions, would expect to have the same or essentially the same results. Therefore, in looking at the instantly claimed compounds and their method of uses as a whole, the claimed compounds would have been suggested to one skilled in the art unless unobvious or unexpected results can be shown.

#### **Objections**

Claims 1-4, and 10 are objected to for containing non-elected subject matter. The claims should be amended to exclude non-elected subject matter and within the scope of elected compound.

# Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 6:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached at (571) 272-0699. The Unofficial fax phone

Art Unit: 1626

number for this Group is (703) 308-7921. The Official fax phone number for this Group is (571)

273-8300.

When filing a FAX in Technology Center 1600, please indicate in the Header (upper

Page 6

right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft

documents and other communications with the PTO that are not for entry into the file of the

application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35

U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be

addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of

record in the application file. PTO employees will not communicate with applicant via Internet

e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive

data could be identified unless there is of record an express waiver of the confidentiality

requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy

published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Group receptionist, whose telephone number is (571) 272-1600.

/Golam M. M. Shameem/

**Primary Examiner** 

Art Unit 1626

Technology Center 1600

Page 7

Art Unit: 1626

Page 8

Art Unit: 1626